基质金属蛋白酶 2 和 9 的高表达可作为霍奇金淋巴瘤患者预后不良的因素。
Increased expression of matrix metalloproteinases 2 and 9 as poor prognosis factor for Hodgkin's lymphoma patients.
机构信息
Universidade de Pernambuco, Instituto de Ciências Biológicas, Recife, PE, Brazil; Universidade Federal de Pernambuco, Departamento de Bioquímica, Recife, PE, Brazil.
Universidade de Pernambuco, Instituto de Ciências Biológicas, Recife, PE, Brazil; Universidade Federal de Pernambuco, Departamento de Citopatologia, Recife, PE, Brazil.
出版信息
J Pediatr (Rio J). 2023 Jan-Feb;99(1):59-64. doi: 10.1016/j.jped.2022.05.004. Epub 2022 Jul 19.
OBJECTIVE
The aim of our study was to evaluate the expression of MMP-2 and MMP-9 as a prognostic factor in patients diagnosed with Hodgkin Lymphoma (HL).
METHODS
In the present study, 45 paraffin biopsies from patients up to 19 years old diagnosed with HL were used in two referral hospitals in the state of Pernambuco, Brazil. Risk groups were classified into favorable and unfavorable, according to Ann Arbor. The expression of matrix metalloproteinases 2 and 9 and their inhibitors was performed by immunohistochemistry (IHC). Data were analyzed using the GraphPad Prism 5 program.
RESULTS
MMP-2 intensity pattern was stronger (>10% of the total field) in patients with stage III/IV and B symptoms. MMP-2 showed an association with the risk group (p = 0.0388). That is, the stronger the MMP-2 marking, the greater the unfavorable risk. However, for MMP-9 there was no difference in the stronger intensity pattern in relation to stages I/II and III/IV, only in the presence of B symptoms. MMP-9 showed an association with B Symptoms (p = 0.0411). Therefore, patients with B symptoms have higher MMP-9 expression.
CONCLUSION
Our results suggest that MMP-2 expression is associated with HL progression. While MMP-9 expression is related to the clinical worsening of these patients. However, further studies are needed to evaluate the exact role of these proteins in hematologic malignancies.
目的
本研究旨在评估 MMP-2 和 MMP-9 的表达作为霍奇金淋巴瘤 (HL) 患者的预后因素。
方法
本研究使用了巴西伯南布哥州两家转诊医院的 45 例 19 岁以下 HL 患者的石蜡活检。根据 Ann Arbor，将风险组分为有利和不利。通过免疫组织化学 (IHC) 检测基质金属蛋白酶 2 和 9 及其抑制剂的表达。使用 GraphPad Prism 5 程序分析数据。
结果
MMP-2 强度模式在 III/IV 期和 B 症状患者中更强 (>10%的总视野)。MMP-2 与风险组相关 (p=0.0388)。即，MMP-2 标记越强，不利风险越大。然而，对于 MMP-9，在 I/II 期和 III/IV 期之间，没有更强的强度模式的差异，只有在存在 B 症状的情况下才有差异。MMP-9 与 B 症状相关 (p=0.0411)。因此，有 B 症状的患者具有更高的 MMP-9 表达。
结论
我们的结果表明，MMP-2 的表达与 HL 的进展有关。而 MMP-9 的表达与这些患者的临床恶化有关。然而，需要进一步研究来评估这些蛋白质在血液恶性肿瘤中的确切作用。
Zotero 插件